Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients

Polski Przeglad Chirurgiczny/ Polish Journal of Surgery

Volumn 83, Issue 12, 2011, Pages 641-645

  Cepowicz, Dariusz ^a   Gryko, Mariusz ^a   Zarȩba, Konrad ^a   Stasiak Bermuta, Anna ^a   Kȩdra, Bogusław ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

adhesion activity; adhesion molecules; CD134; CD137; colorectal cancer

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CANCER STAGING; COLORECTAL TUMOR; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

AGED; ANTIGENS, CD137; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, OX40; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857729550     PISSN: 0032373X     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10035-011-0102-9     Document Type: Article

References (18)

1. Chen S- H, Pham-Nguyen KB, Marinet O et al.: ReJection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Molecular Therapy 2000; 2(1): 39-46.
2. Mazollini G, Murillo O, Atorrasagasti C et al.: Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 2007; 13(44): 5822-31. (Pubitemid 350148499)
3. Petty JK, He K, Corless CL et al.: Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512-18. (Pubitemid 34603419)
4. Tebutt NC, Cattell E, Midgley R et al.: Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000-15. (Pubitemid 34442328)
5. Marinet O, Ermekova V, Qiao JQ et al.: Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in mouse model. J National Cancer Institute 2000; 92(11): 931-36. (Pubitemid 30429194)
6. Sanz L, Blanco B, Alvarez-Vallina L: Antibodies and gene therapy: teaching old ?magic bullets? new trics. Trends in immunology 2004; 25(2): 85-91. (Pubitemid 38167489)
7. Cragg MS, French RR, Glennie MJ: Signaling antibodies in cancer therapy. Cancer 1999; 11: 541-47. (Pubitemid 29462130)
8. Mayer-Kuckuk P, BanerJee D, Kemeny N et al.: Molecular therapies of colorectal cancer metastatic to the liver. Molecular Therapy 2002; 5(5): 492-500. (Pubitemid 34546078)
9. Pan P-Y, Zang Y, Weber K et al.: OX40 ligation enhances primary and memory cytotoxic L lymphocyte responses in an immunotherapy for hepatic colon metastases. Molecular Therapy 2002; 6(4): 528-36. (Pubitemid 35214875)
10. Ballestrero A, Boy D, Moran E et al.: Immunotherapy with dendritic cells for cancer. Advanced Drug Delivery Reviews 2008; 60: 173-83. (Pubitemid 350236398)
11. Tirapu I, Arina A, Mazollini G et al.: Improving efficacy of interleukin-12-transfected dendritic cells inJected into murine colon cancer with colon cancer with anti-CD-137 monoclonal antibodies and alloantigens. Int J Cancer 2004; 110: 51-60. (Pubitemid 38507203)
12. Mocellin S, Nitti D: Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Medicinal Research Reviews 2008; 28(3): 413-44. (Pubitemid 351590541)
13. Weinberg AD, Rivera M-M, Prell R et al.: Engagement of the OX-40 receptor in vivo enhances antitumor immunity. The J Immunology 2000; 164: 2160-69. (Pubitemid 30108775)
14. Croft M: Costimulation of T cells by OX-40, 4-1BB, and CD27. Cytokine Growth Factor Rec 2003; 14: 265-73. (Pubitemid 36693146)
15. Dimberg J, Hugander A, Wagsater D: Expression of CD137 and CD137 ligand in colorectal cancer patients. Oncology Reports 2006; 15: 1197-1200.
16. Zhang N, Sadun RE, Arias RS et al.: Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clinical Cancer Research 2007; 13: 2758-67. (Pubitemid 46788045)
17. Cepowicz D, Stasiak-Bermuta A, Zalewski B et al.: Assessment expresion of the adhesion molecules, CD134 and CD137, In patients with colorectal cancer by flow cytometry. Ann Acad Medicae Bialostocensis 2004; 49: suppl 1: 34-36.
18. Vonderheide RH, June CH: A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cells immunotherapy. Immunol Res 2003; 27: 341-56.